Otsuka Pharmaceutical Co. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Otsuka Pharmaceutical Co. Ltd.
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.
The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.
A Phase III study testing the ligand-conjugated anti-sense medicine in hereditary angioedema read out positively, but the drug would join a competitive market if approved.
"Otsuka is very, very committed to nutraceuticals generally, and supplements specifically,” says Pharmavite CEO Jeff Boutelle.
- Medical Devices
- OTC, Consumer
In Vitro Diagnostics
- Chemistry, Immunoassay
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.